| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
5-Bromothiophene-2-carbaldehyde does not have a defined pharmacological target of its own as it is a synthetic intermediate rather than a drug substance. However, it is widely used as a building block for the synthesis of various biologically active compounds. Through palladium-catalyzed cross-coupling reactions, this bromide can be converted to a wide range of heteroaryl products with potential activity against various biological targets. Thiophene-containing compounds are found in numerous pharmaceuticals with diverse activities including anticancer, anti-inflammatory, antimicrobial, and CNS-active properties. The aldehyde group can be further derivatized to amines, alcohols, acids, and other functional groups.
|
|---|---|
| ln Vitro |
5-Bromo-2-thiophene carboxaldehyde is utilized to make carboxaldehyde 5-[18F]fluoro-2-2-thiophene. It has also been applied in biological research on the anti-inflammatory and anti-tumor properties of the rhizomes of marine mangroves.
In vitro, 5-Bromothiophene-2-carbaldehyde is primarily used as a chemical reagent and synthetic intermediate rather than being evaluated for direct biological activity. It is employed in the synthesis of various pharmaceutical compounds that are subsequently tested in in vitro assays. The compound is soluble in common organic solvents such as DMSO, DMF, dichloromethane, and THF, making it suitable for use in solution-phase organic synthesis. As a brominated heteroarene, it is a common building block for the construction of drug-like molecules in medicinal chemistry workflows via cross-coupling chemistry. |
| ln Vivo |
In vivo activity data for 5-Bromothiophene-2-carbaldehyde itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from it.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 5-Bromothiophene-2-carbaldehyde is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of approximately 191 g/mol and moderate lipophilicity (estimated logP ~2.0-2.5). The bromine atom serves as a versatile handle for cross-coupling reactions, while the aldehyde group enables condensation reactions for the introduction of various substituents in structure-activity relationship studies.
|
| Cell Assay |
For in vitro cell-based experiments, 5-Bromothiophene-2-carbaldehyde is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium. The thiophene moiety may contribute to the overall electronic properties and biological activity of the final drug candidates.
|
| Animal Protocol |
In vivo animal studies using 5-Bromothiophene-2-carbaldehyde are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints. Specific protocols for the intermediate compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-Bromothiophene-2-carbaldehyde as a standalone compound are not characterized in the literature, as it is a synthetic intermediate rather than a drug candidate. The compound has a molecular weight of approximately 191 g/mol, which is within the favorable range for oral bioavailability. The aldehyde group may be subject to rapid metabolism through aldehyde dehydrogenase or aldehyde oxidase pathways. The bromine substituent may be subject to oxidative debromination. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
5-Bromothiophene-2-carbaldehyde is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated heteroaromatic aldehyde, it may pose risks of skin and eye irritation. The aldehyde group may be irritating to the respiratory tract. Specific LD₅₀ values and acute toxicity classifications are not available in the public literature. Standard safety practices include the use of personal protective equipment (gloves, safety goggles, lab coat), working in a fume hood, and avoiding inhalation and skin contact. The compound is intended for research use only.
|
| Additional Infomation |
5-Bromothiophene-2-carbaldehyde (CAS 4701-17-1) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are in organic synthesis as a building block for the construction of complex molecules through cross-coupling and condensation reactions. The thiophene ring is a common heterocycle found in numerous pharmaceuticals and bioactive compounds. The bromine atom provides a versatile handle for introducing diverse substituents via palladium-catalyzed coupling reactions, while the aldehyde group enables reductive amination and condensation chemistry. The compound is used in medicinal chemistry for the synthesis of drug candidates and in materials science for the preparation of organic electronic materials. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C5H3BROS
|
|---|---|
| Molecular Weight |
191.05
|
| Exact Mass |
189.908
|
| CAS # |
4701-17-1
|
| PubChem CID |
78428
|
| Appearance |
Yellow to brown <55°C solid powder,>55°C liquid
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
230.7±0.0 °C at 760 mmHg
|
| Melting Point |
104-6ºC
|
| Flash Point |
98.9±0.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
1.97
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
8
|
| Complexity |
96.4
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(SC(=C1)Br)C=O
|
| InChi Key |
GFBVUFQNHLUCPX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3BrOS/c6-5-2-1-4(3-7)8-5/h1-3H
|
| Chemical Name |
5-bromothiophene-2-carbaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2342 mL | 26.1712 mL | 52.3423 mL | |
| 5 mM | 1.0468 mL | 5.2342 mL | 10.4685 mL | |
| 10 mM | 0.5234 mL | 2.6171 mL | 5.2342 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
